中国继续医学教育
中國繼續醫學教育
중국계속의학교육
China Continuing Medical Education
2015年
25期
104-105
,共2页
王大志%赵许亚%何伟%周石
王大誌%趙許亞%何偉%週石
왕대지%조허아%하위%주석
介入治疗法%肿瘤间质治疗%免疫功能
介入治療法%腫瘤間質治療%免疫功能
개입치요법%종류간질치료%면역공능
Interventional therapy%Interstitial therapy%Immune function
目的:探究介入治疗法联合肿瘤间质治疗方法对肝癌患者免疫功能的影响分析。方法选取自2011年1月~2015年1月我院收治的196例中晚期肝癌患者,随机分为实验组和对照组,各98例。对照组采用经肝动脉化疗栓塞术(TACE)进行治疗,实验组在对照组的基础上联合肿瘤间质治疗。观察两组患者免疫功能指标。结果经过治疗后,实验组患者的 CD3+和 CD4+高于对照组,血清 SIL-2R 明显低于对照组,经对比,两组差异具有统计学意义,即P <0.05。两组的CD8+比较,差异不具有统计学意义,即 P >0.05。结论采用介入治疗法联合肿瘤间质治疗方法对肝癌患者进行治疗,不仅能够改善患者的免疫功能,还可促进患者身体恢复。
目的:探究介入治療法聯閤腫瘤間質治療方法對肝癌患者免疫功能的影響分析。方法選取自2011年1月~2015年1月我院收治的196例中晚期肝癌患者,隨機分為實驗組和對照組,各98例。對照組採用經肝動脈化療栓塞術(TACE)進行治療,實驗組在對照組的基礎上聯閤腫瘤間質治療。觀察兩組患者免疫功能指標。結果經過治療後,實驗組患者的 CD3+和 CD4+高于對照組,血清 SIL-2R 明顯低于對照組,經對比,兩組差異具有統計學意義,即P <0.05。兩組的CD8+比較,差異不具有統計學意義,即 P >0.05。結論採用介入治療法聯閤腫瘤間質治療方法對肝癌患者進行治療,不僅能夠改善患者的免疫功能,還可促進患者身體恢複。
목적:탐구개입치요법연합종류간질치료방법대간암환자면역공능적영향분석。방법선취자2011년1월~2015년1월아원수치적196례중만기간암환자,수궤분위실험조화대조조,각98례。대조조채용경간동맥화료전새술(TACE)진행치료,실험조재대조조적기출상연합종류간질치료。관찰량조환자면역공능지표。결과경과치료후,실험조환자적 CD3+화 CD4+고우대조조,혈청 SIL-2R 명현저우대조조,경대비,량조차이구유통계학의의,즉P <0.05。량조적CD8+비교,차이불구유통계학의의,즉 P >0.05。결론채용개입치요법연합종류간질치료방법대간암환자진행치료,불부능구개선환자적면역공능,환가촉진환자신체회복。
Objective To explore the effect of the treatment of interventional therapy combined with interstitial therapy on the immune function of patients with liver cancer. Methods From January 2011 to January 2015, 196 cases of patients with advanced liver cancer were randomly divided into experimental group and control group, each of 98 cases. The control group was treated with transcatheter arterial chemoembolization (TACE), and the experimental group was treated with the combination of tumor interstitial therapy based on the control group. Immune function of the two groups were observed. Results After treatment, the CD3+ and CD4+ in the experimental group were significantly higher than those in the control group, the serum SIL and 2R were significantly lower than those in the control group, the difference was statistically significant, that is, P<0.05. The difference of CD8+ in the two groups was not statistically significant, that is, P>0.05. Conclusion Interventional therapy for treatment of liver cancer patients, not only can improve the immune function, but also promote the recovery of patients.